Lafayette Regional Health Center is proud to be part of the Sarah Cannon Cancer Institute HCA Midwest Health cancer network, providing local access to innovative clinical research trials, tumor profiling and genetic counseling; you can receive top cancer care in the comfort of your community hospital.
As part of the Sarah Cannon Cancer Institute at HCA Midwest Health, Lafayette Regional Health Center is a network-accredited cancer program. Accredited by the American College of Surgeons’ Commission on Cancer (CoC) quality program, the Sarah Cannon HCA Midwest Health cancer centers exceed the quality care standards set out by the CoC and consistently provide excellence in the delivery of comprehensive patient-centered care across our network of hospitals.
By addressing patient-centered needs and delivering quality care measured against national standards, patients and families have access to world-class, cutting-edge and innovative oncology services in their local communities. Patients receive the best cancer care close to home, while having access to the latest specialized technologies and clinical trial expertise available across the network.
Free Risk Assessments
Eating right and exercising are great steps toward leading a healthy life, but did you know your family history, age, and countless other factors can still put you at risk for health problems? Try our free risk assessments below to estimate your personal risk of developing breast, colon or rectal cancer, and identify your different types of risk factors.
For more information, contact us at (660) 259-6884 or visit hcamidwest.com. In addition to comprehensive prevention tools, diagnostics, cutting-edge therapies and surgical treatments, Sarah Cannon Cancer Institute HCA Midwest Health also offers a cancer wellness program to help support you every step of the way.
The Lafayette Regional Health Center is in the process of becoming accredited by the American College of Surgeons, Commission on Cancer (CoC). The CoC publishes the Cancer Programs Practice Profile Reports (CP3R) which includes 6 measures for breast cancer.
The (CP³R) measurement helps facilities to:
- Ensure patients are treated according to recognized standards of care,
- Promote quality improvement activities, and
- Accurately compare clinical performance among CoC accredited cancer programs.
We compared our 2014 breast cases receiving hormone therapy to the most current CoC results of 2013:
|Accountability Measure||Lafayette Regional Health Center||Missouri||National|
|Tamoxifen or third generation aromatase inhibitor is considered or administered within 1 year (365 days) of diagnosis for women with AJCC T1cN0M0, or stage IB –III hormone receptor positive breast cancer.||100%||94.3%||92.4%|
*The accountability measures were agreed upon by the NQF (National Quality Forum) who facilitated an agreement between the CoC (Commission on Cancer), ASCO (American Society for Conical Oncology) & NCCN (National Comprehensive Cancer Network).
Source: Commission on Cancer, National Cancer Database